MedTrace Logo

AVAVA MIRIA General Use

NCT06868615 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-03-11

No results posted yet for this study

Summary

A general protocol to treat a variety of dermatologic conditions and collect patient feedback.

Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.

Conditions

  • Acne
  • Acne Scars - Mixed Atrophic and Hypertrophic
  • Scars
  • Wrinkle
  • Pigment; Lesion
  • Skin Texture Disorder

Interventions

DEVICE

AVAVA

1550nm Non-Ablative Fractional Laser

Sponsors & Collaborators

  • AVAVA, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2027-12-30
Completion
2027-12-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06868615 on ClinicalTrials.gov